Ipsen Pharma

Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors (2020) Grenader T, Pavel ME, Ruszniewski PB, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Journal article Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study (2020) Caplin ME, Pavel ME, Phan AT, Cwikla JB, Sedlackova E, Thanh XMT, Wolin EM, Ruszniewski P Journal article Baseline characteristics from CLARINET FORTE: Evaluating lanreotide autogel (LAN) 120mg every 14 days in patients with progressive pancreatic or midgut neuroendocrine tumours during a standard first-line LAN regimen (2019) Ruszniewski P, Cwikla J, Lombard-Bohas C, Borbath I, Shah T, Pape UF, Thanh XMT, et al. Conference contribution Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors (2019) Pavel ME, Phan AT, Wolin EM, Mirakhur B, Liyanage N, Pitman Lowenthal S, Fisher GA, Vinik AI Journal article Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors (2019) Dromain C, Pavel ME, Ruszniewski P, Langley A, Massien C, Baudin E, Caplin ME Journal article Safety and Efficacy of 14-Day Dosing Interval of Lanreotide Autogel/Depot (LAN) for Pts with Pancreatic or Midgut Neuroendocrine Tumours (NETs) Progressing on LAN Every 28 Days: Prospective, Open-label, International, Phase 2 CLARINET FORTE Study (2019) Pavel ME, Dromain C, Thanh TXM, Houchard A Conference contribution Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR (2018) Cella D, Beaumont JL, Hudgens S, Marteau F, Feuilly M, Houchard A, Lapuerta P, et al. Journal article Final analysis of time to subsequent disease progression/death in patients with metastatic enteropancreatic neuroendocrine tumours progressing under placebo and switched to lanreotide Autogel/depot 120mg in the CLARINET open-label extension (2018) Pavel ME, Cwikla J, Wolin E, Phan A, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution Final Progression-Free Survival Analyses for Lanreotide Autogel/Depot 120 mg in Metastatic Enteropancreatic Neuroendocrine Tumors: The CLARINET Extension Study (2018) Wolin EM, Pavel ME, Cwikla JB, Phan AT, Raderer M, Sedlackova E, Cadiot G, et al. Conference contribution BIOCHEMICAL RESPONSES IN SYMPTOMATIC AND ASYMPTOMATIC PATIENTS WITH NEUROENDOCRINE TUMORS: POOLED ANALYSIS OF 2 PHASE 3 TRIALS (2018) Mirakhur B, Pavel ME, Pommier RF, Fisher GA, Phan AT, Massien C, Liyanage N, et al. Journal article